Xencor, Inc. $XNCR Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP lessened its stake in Xencor, Inc. (NASDAQ:XNCR) by 27.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 80,000 shares of the biopharmaceutical company’s stock after selling 29,554 shares during the quarter. Seven Fleet Capital Management LP owned 0.11% of Xencor worth $965,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Tower Research Capital LLC TRC raised its holdings in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in Xencor during the 2nd quarter worth approximately $79,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Xencor in the 4th quarter valued at approximately $81,000. iSAM Funds UK Ltd purchased a new stake in shares of Xencor in the 2nd quarter valued at approximately $122,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Xencor in the 3rd quarter valued at $139,000.

Wall Street Analyst Weigh In

XNCR has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Wedbush restated an “outperform” rating and issued a $26.00 price target on shares of Xencor in a research note on Thursday. Wall Street Zen downgraded Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. lifted their price target on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Finally, Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Xencor Stock Performance

XNCR opened at $20.21 on Friday. The business’s 50-day simple moving average is $14.86 and its 200-day simple moving average is $13.15. Xencor, Inc. has a one year low of $6.92 and a one year high of $21.76. The stock has a market capitalization of $1.50 billion, a P/E ratio of -8.83 and a beta of 0.86.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm’s revenue for the quarter was down 86.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.66) earnings per share. On average, equities research analysts forecast that Xencor, Inc. will post -3.76 EPS for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.